 LAVAL, Québec, May 17, 2021 GLOBE NEWSWIRE -- Acasti Pharma Inc. Acasti or the Company Nasdaq: ACST and TSX-V: ACST today announced that, on May 11, 2021, the Company received notice from the Nasdaq Listing Qualifications Department the Staff indicating that, based upon the Companys non-compliance with the 1.00 bid price requirement set forth in Nasdaq Listing Rule 5550a the Rule as of May 10, 2021, the Companys securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel the Panel. The Company has previously disclosed and expected such notification from Nasdaq and believes it has options to regain compliance, preferably in connection with its proposed acquisition of Grace Therapeutics, Inc. Grace as is often done in connection with similar transactions. 